DALLAS, Oct. 16, 2009 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring anti-cancer drug developer GenVec Inc. (Nasdaq:GNVC). The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.
The investment report on GenVec Inc. (Nasdaq:GNVC) should be of particular interest to comparable companies: Schering-Plough Corp. (NYSE:SGP), Sangamo Biosciences Inc. (Nasdaq:SGMO), SuperGen Inc. (Nasdaq:SUPG) and Biogen Idec Inc. (Nasdaq:BIIB).
The full report is available at: http://www.stockpreacher.com/n/GNVC
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/StockPreacher
GenVec Inc. (GNVC), a clinical stage biopharmaceutical company, engages in the development of gene-based therapeutic drugs and vaccines. Its lead therapeutic candidate, TNFerade, is currently in a pivotal, phase III clinical study (PACT) in locally advanced pancreatic cancer. In addition, TNFerade is currently being evaluated for its potential use in the treatment of several other cancers, including esophageal cancer, rectal cancer, and head and neck cancer. The Company has strategic alliances and research contracts with the U.S. Department of Homeland Security, the U.S. Department of Agriculture, PATH Malaria Vaccine Initiative (MVI), the U.S. Naval Medical Research Center, and the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases of the National Institutes of Health.
Message Board Search for GNVC: http://www.boardcentral.com/boards/GNVC
In the report, the analyst notes:
"On September 24, the Company announced it received the fourth-year funding from the National Institute of Allergy and Infectious Disease (NIAID), which is part of the $52 million, five-year contract for the production of HIV vaccines. For the fourth year, GNVC will reportedly receive up to $2.3 million, which will support the generation of HIV vaccine candidates with its alternate adenovirus serotype technology.
"The Company stated in its recent 10-Q filing that it will continue to look for government sponsored research collaborations and grants to help offset future anticipated losses from operations, as it expects to continue to rely on government funding for a significant portion of its revenues for the next few years and, to a lesser extent, interest income."
To read the entire report visit: http://www.stockpreacher.com/n/GNVC
See what investors are saying about these stocks at: http://www.stockhideout.com/
StockPreacher.com is a small-cap research and investment commentary provider. StockPreacher.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on StockPreacher, please visit: http://www.stockpreacher.com
StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a Web site wholly-owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, StockPreacher.com, for complete risks and disclosures.
CONTACT: StockPreacher.com Jeff Bishop (469)-252-3505 email@example.com